Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgement of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs.
Thank you for your interest in Biotron.
Regards Michelle
Dr Michelle Miller | CEO & Managing Director | Biotron Limited
- Forums
- Charts
- Award winning BIT
Dr Carolyn Luscombe, Head of Research and Development, has...
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
0.002(7.69%) |
Mkt cap ! $25.26M |
Open | High | Low | Value | Volume |
2.6¢ | 2.8¢ | 2.6¢ | $5.947K | 226.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 256882 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 173924 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 256882 | 0.026 |
5 | 178646 | 0.025 |
4 | 396000 | 0.024 |
2 | 430000 | 0.023 |
5 | 4245555 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 173924 | 3 |
0.029 | 555600 | 4 |
0.030 | 90000 | 3 |
0.031 | 109129 | 2 |
0.032 | 500000 | 1 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |